Evaluating the early impacts of delisting high-strength opioids on patterns of prescribing in Ontario
Guan Q, Khuu W, Martins D, Tadrous M, Chiu M, Do MT, Gomes T. Health Promot Chronic Dis Prev Can. 2018; 38(6):256-62. Epub 2018 Jun 1.
Publications
The burden of opioid-related mortality in the United States
Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. JAMA Network Open. 2018; 1(2):e180217. Epub 2018 Jun 1.
Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study
Liu EY, Smith LM, Ellis AK, Whitaker H, Law B, Kwong JC, Farrington P, Lévesque LE. CMAJ. 2018; 190(21):E648-55. Epub 2018 May 28.
A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride
Antoniou T, Macdonald EM, Yao Z, Gomes T, Tadrous M, Ho JM, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. BMC Musculoskelet Disord. 2018; 19:160. Epub 2018 May 22.
Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study
Pasricha SV, Tadrous M, Khuu W, Juurlink DN, Mamdani MM, Paterson JM, Gomes T. Pain. 2018; 159(8):1562-8. Epub 2018 May 16.
Identifying diabetes cases from administrative data: a population-based validation study
Lipscombe LL, Hwee J, Webster L, Shah BR, Booth GL, Tu K. BMC Health Serv Res. 2018; 8:316. Epub 2018 May 2.
Risk factors for return to the emergency department for asthma: a population-based study
To T, Zhu J, Ryckman K, Gershon A. J Allergy Clin Immunol Pract. 2018; 6(6):1907-13.e4. Epub 2018 Apr 30.
Publicly funded oral chronic hepatitis B treatment patterns in Ontario over 16 years: an ecologic study
Tadrous M, Brahmania M, Martins D, Knowles S, Janssen HLA, Mamdani MM, Juurlink DN, Gomes T. J Manag Care Spec Pharm. 2018; 24(5):464-8. Epub 2018 Apr 26.
Measuring the burden of opioid-related mortality in Ontario, Canada
Gomes T, Greaves S, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. J Addict Med. 2018; 12(5):418-9. Epub 2018 Apr 25.
Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada
Minhas R, Tadrous M, Elterman D, Gomes T. Neurourol Urodyn. 2018; 37(5):1693-700. Epub 2018 Apr 23.